The Danish drugmaker said weekly injections of the highest dose of the medication known generically as semaglutide slashed the risk of heart attack, stroke and heart disease-related deaths in people who were overweight or obese and had known cardiovascular disease, but not type 2 diabetes....
Results from the trial, conducted on more than 17, 000 people in 41 countries, could bode well for all drugs in Wegovy's class because it may make insurers and other health care bill payers more likely to
综合
ABC新闻-商业新闻
2023-08-09 00:00:00.0